Ever since the introduction of the Steritas Glucocorticoid Toxicity Index (GTI) in 2017, there has been a remarkable surge in the number of clinicians and clinical researchers using Steritas's growing suite of steroid-toxicity assessment tools. Over the past six months, adoption has continued to grow at an exponential rate.
In March this year, we reported the Steritas eCOA suite had been used in more than 70 clinical trials, in 600 sites spread across 80 countries.
Today, Steritas instruments have been adopted across more than 1000 trial and clinic sites.
This surge in demand reflects the growing recognition of the importance of steroid-toxicity assessment in both pharmaceutical research and clinical practice. Glucocorticoids are amongst the most prescribed medications in the world, with 50 million people, or 1% of the world's adult population taking them long-term.[1] They are both a panacea and a poison and the toxicities associated with their usage can be likened to an epidemic.
The GTI, its pediatric sibling the pGTI and the recently introduced GTI-MD, have now been used in more than 25 disease indications, including (but not limited to):
Asthma
Autoimmune blistering diseases
Bullous pemphigoid
Pemphigus foliaceus
Pemphigus vulgaris
Congenital adrenal hyperplasia
Idiopathic Inflammatory Myopathies
Dermatomyositis
Inflammatory myopathy
IgG4-Related Disease
Inflammatory Arthritis
Juvenile idiopathic arthritis (pediatric)
Rheumatoid arthritis
Interstitial lung disease
Myasthenia gravis
Primary Glomerular Diseases
Minimal change disease (pediatric)
Nephrotic syndrome
Primary membranous nephropathy and podocytopathies
Sarcoidosis
Cardiac
Pulmonary
Systemic lupus erythematosus (SLE)
Lupus nephritis
Pediatric lupus nephritis
Vasculitis
Aortitis
Behcet’s Disease
Giant cell arteritis (GCA)
Granulomatosis with polyangiitis (GPA)
Kawasaki’s disease (pediatric)
Microscopic polyangiitis (MPA)
Polymyalgia rheumatica (PMR)
Takayasu’s arteritis
With this rapid growth in adoption, it's perhaps no surprise that Steritas was recently named Start-Up of the Year at the 2023 SAMPS Awards. The annual SAMPS Awards celebrate companies doing important work in the life sciences, and Steritas was recognized among dozens of the best that the industry has to offer.
Laura Haldane of SciLeads presented the award, recognizing Steritas’ support of scientific rigor in clinical trials by quantifying steroid-toxicity to enable the development of steroid-sparing therapies, to change steroid-prescribing patterns across health systems, and to empower patients to engage in their own care.